Corbus Pharmaceuticals (NASDAQ:CRBP) has announced the completion of enrollment for the dose-escalation portion of its bridging Phase 1 clinical trial of CRB-701 (SYS6002) in patients with advanced solid tumors expressing high levels of Nectin-4.
The company states that the dose-escalation segment of its open label study is being conducted both in the U.S. and the UK. Corbus anticipates releaseing the first data from this phase in Q1 2025.
Corbus’ CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. It features a site-specific, cleavable linker and a homogenous drug-to-antibody ratio of 2, utilizing MMAE as the payload. Nectin-4 is a clinically validated tumor-associated antigen, particularly in urothelial cancer.
